Amryt Pharma Share Discussion Threads

[2wp] 22/3/2024 06:00

Having just got payment for the milestone CVR's I'm assuming business in now concluded? Or is there still an interest in the revenue CVR's? Many thanks.

[waterloo01] 28/2/2024 14:14

Thanks Timbo003. Makes sense.

[timbo003] 28/2/2024 11:50

>>>Waterloo, I suspect those revenue CVRs are worth zilch and will be removed from your account before long.

I have some of those too which resulted from me holding a few Amryt shares in my Halifax share dealing (HSD) account when they were quoted on AIM. I sold the shares held in the HSD account a few weeks before they switched to Nasdaq, yet the EMA CVRs and the revenue CVRs stayed showing in the account. Having sold my HSD amryt shares prior to the takeover by Chiesi, I did not qualify for the later FDA approval CVRs or the fast track approval CVRs, although fortunately (for me) I am entitled to the proceeds of these two CVRs from the certificated Amryt shares I held - which I did not sell when they switched to Nasdaq

[bazworth] 28/2/2024 11:17

We hold some CVR’ in our ISA. Iii are investigating!!

[waterloo01] 28/2/2024 10:01

Does this make any sense to anyone? From HL

Amryt Pharma plc have made a payment for CVRs which were distributed following a scheme of arrangement in 2023. These 'Milestone' CVRs are different to the 'Revenue' CVRs that you hold.

The 'Revenue' CVRs that you hold were distributed to shareholders back in 2019, and have the following condition to meet before realising a distribution: 'The Revenue CVR will pay out New Amryt shares or loan notes if the 12 monthly revenue from AP101 exceeds USD75 million before 30 June 2024'. We are yet to receive any notice that these conditions have been met, nor have we received the proceeds for the 'Revenue' CVRs which you hold. If these are received we will credit your account without delay, and if the conditions for the CVRs are not met then they will be cancelled without value and removed from your account.

I hope this has been of assistance. Should you have any further queries, please do not hesitate to get back in touch.

[curnic1] 22/2/2024 23:36

Got my cash yesterday,in my ii account.

[timbo003] 22/2/2024 20:13

the wife was credited with the cash in her Halifax dealing account on Tuesday (morning). I held Amryt as certificates, but nothing in the post yet for me.

[iamnotanumber6] 22/2/2024 20:12

I got mine yesterday!
Am I right in thinking that's it for CLNs? I still seem to have an older one sitting in my account, and can't remember if that has actually expired.

[bazworth] 22/2/2024 20:00

not as yet!

[waterloo01] 22/2/2024 14:54

Anyone seen any money into accounts?

[curnic1] 20/2/2024 02:29

Redemption
Redemption amount: USD0.30
Redemption date: 16th February 2024
Pay date: Upon Receipt
Amryt Pharma PLC has announced the compulsory Redemption of all the remaining Contingent Value Rights in issue,
at a price of USD0.30 per CVR.
Please note that the proceeds may be subject to Section 302 processing and as such may be treated as Income or
Capital as determined by the company.
If the proceeds are treated as an income payment then the corresponding tax may be debited at a later date than the
receipt of the proceeds.
Should Shareholders require further information regarding Section 302 processing, then they are advised to speak to
their tax advisers as we are unable to offer tax advice.
The redemption date is 16th February 2024. Accounts will be updated upon receipt of the cash from our Custodian.
Your account will be updated upon receipt of the proceeds but in some circumstances there may be delays in the
proceeds being credited to us. Please allow 10 working days for your account to be updated.

[curnic1] 19/2/2024 22:58

Update regarding CVR from ii

Redemption
Redemption amount: USD0.20
Redemption date: 16th February 2024
Pay date: Upon Receipt
Amryt Pharma PLC has announced the compulsory Redemption of all the remaining Contingent Value Rights in issue,
at a price of USD0.20 per CVR.
Please note that the proceeds may be subject to Section 302 processing and as such may be treated as Income or
Capital as determined by the company.
If the proceeds are treated as an income payment then the corresponding tax may be debited at a later date than the
receipt of the proceeds.
Should Shareholders require further information regarding Section 302 processing, then they are advised to speak to
their tax advisers as we are unable to offer tax advice.
The redemption date is 16th February 2024. Accounts will be updated upon receipt of the cash from our Custodian.
Your account will be updated upon receipt of the proceeds but in some circumstances there may be delays in the
proceeds being credited to us. Please allow 10 working days for your account to be updated.

[richpassi] 26/1/2024 16:24

Only came on to see if anyone still here and see that pleasant news ;)

[moorsie2] 24/1/2024 09:08

Thanks Timbo003

I read that paragragh before and still cannot find anything on when they settle with CVR holders... do we have to wait until the end of the year as per the date outlined above or should it be settled now that all conditions have been met?

[timbo003] 22/1/2024 12:28

From the acquisition documentation:

Payments referred to below are per ordinary share (5 ordinary shares = 1 ADR)

[brummy_git] 22/1/2024 12:01

Well spotted guys. Now that's a nice way to kick-off 2024. Top trumps

[timbo003] 22/1/2024 11:27

Thanks Moorsie, here's the link:

[moorsie2] 22/1/2024 09:54

I see now phase 2 of the payment clause has also been met. FDA confirmed on 11th Jan

Anyone know when 2.50 dollars will be settled to CVR holders?

[papillon] 21/12/2023 15:56

Brummy_git 20 Dec '23 - 11:21 - 1 of 1
0 0 0
Now that's a nice (& somewhat surprising) Xmas pressie.

The Food and Drug Administration (FDA) has approved Filsuvez (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months of age and older with junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB).

"Findings showed 41.3% of patients treated with Filsuvez had first complete closure of target wound within 45 days vs 28.9% of patients who received placebo gel."

$1 extra per CVR held, plus the future possibility now of being awarded another $1/share if Chiesi receive an FDA priority review voucher



The above is copied from the AMRYT thread

[jamie1952] 14/7/2023 11:25

How do you sell the share certificate ?

[richpassi] 20/1/2023 12:41

Not being impatient at all I wasn't asking if anyone had received the CVR's, only interested to see who was going to wait until 'Holding Date' announced as some people have obviously already sold and won't get the CVR allowance. Luckily I don't need to bank the cash at the moment and have no intention of reinvesting it, so waiting to receive something that may only have a slight chance of approval, and at no cost to me, is a free punt ..... Amryt's done me ok Thanks to the Italians.All the patients in world ;)

[dcme] 20/1/2023 10:22

The FDA has already rejected Filsuvez for EB based on P3 results which showed little if any efficacy - The new CVRs have the following conditions so I wouldn't be holding my breath:

"US$1.00 per ADS upon FDA approval of Filsuvez® and US$1.50 per ADS upon successful receipt of a Priority Review Voucher from the FDA"

[iamnotanumber6] 20/1/2023 01:04

Well I'm still here! I think you're being a little impatient - the takeover was only announced 12 days ago, and it DID say it was completing in the first half of the year....

[richpassi] 19/1/2023 19:23

Has everyone sold out and left me as last man standing or anyone else waiting for the new CVR's ?